drugset / Trial / NCT02376972

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

NCT02376972

Phase 2 Terminated 392 enrolled Alfasigma S.p.A. Parexel · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS

Timeline

Start
2015-04
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metronidazole Small molecule Other
Subject Rifaximin Other / unclassified 25 mg Other
Subject Rifaximin Other / unclassified 100 mg Other

Indications